SAB Biotherapeutics, Inc. SABS
Set alert
At close
Pre-market · Nov 3, 6:11 AM ET
Day range unavailable
- YTD
- -11.76%
- 1 year
- +1.54%
- Open
- —
- Prev close
- 3.30
- Mkt cap
- 300.26M
- Vol
- 0
- Avg vol
- 539.15K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
YTD chart
Signals (65)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 4 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
Newest 20 of 65.
Key statistics
- Market cap
- 39.50M
- Enterprise value
- 17.04M
- Trailing P/E
- 0.00
- Forward P/E
- -1.56
- PEG ratio
- 0.00
- Price / sales
- 26.11
- Price / book
- 1.07
- EPS (TTM)
- -6.30
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.51M
- Revenue growth
- 0.00%
- Free cash flow
- -26.31M
- Total cash
- 30.40M
- Total debt
- 4.52M
- Return on equity
- -174.73%
- Shares outstanding
- 9.23M
- Short % of float
- 1.41%
- 50-day average
- 3.29
- 200-day average
- 3.35
Analyst view
Consensus: none
- Target (low)
- 6.00
- Target (mean)
- 12.40
- Target (high)
- 25.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.21.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.07 | -1.12 | -0.05 | -4.67% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | -0.79 | +0.34 | +30.09% |
| Aug 8, 2024 | Jun 1, 2024 | -1.13 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | -0.98 | -0.54 | +0.44 | +44.90% |
| Apr 1, 2024 | Dec 1, 2023 | -0.64 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 9, 2024 | Craig-Hallum | init | — | Buy |
| Sep 12, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Sep 9, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 28, 2024 | Oppenheimer | init | — | Outperform |
| Aug 12, 2024 | Chardan Capital | main | Buy | Buy |
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sabbiotherapeutics.com
News
- SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
- FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
- SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes
- Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13
- Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday
- Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12
- HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target
- Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11
Your note
Sign in to keep a note on SABS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELLIAS HELEN K | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| KING MICHAEL | Chief Financial Officer | Purchase | Nov 29, 2023 | 5,000 |
| KROPOTOVA ALEXANDRA | Officer | Stock Award(Grant) | Mar 13, 2023 | 275,000 |
| MOIN ANDREW D. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
| REICH SAMUEL J. | Officer and Director | Purchase | Nov 28, 2023 | 766,699 |
| SESSA CAPITAL MASTER, L.P. | Director | Conversion of Exercise of derivative security | Nov 23, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.94% | 917,826 | 3.93M | Sep 29, 2024 |
| RTW Investments LP | 6.88% | 635,276 | 2.72M | Sep 29, 2024 |
| Marshall Wace LLP | 4.98% | 459,168 | 1.97M | Sep 29, 2024 |
| Sessa Capital IM, L.P. | 4.97% | 458,457 | 1.96M | Sep 29, 2024 |
| Vanguard Group Inc | 2.99% | 276,336 | 1.18M | Sep 29, 2024 |
| HB Wealth Management, LLC | 1.18% | 108,600 | 464.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 232,567 | 995.39K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.46% | 42,636 | 182.48K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 41,315 | 176.83K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 14,370 | 61.50K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 12,940 | 55.38K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 9,834 | 42.09K | Oct 30, 2024 |